Various studies have shown that the deletion of EGFR exon 19 (del) and mutation of L858R on exon 21 in most NSCLC cells are sensitive to EGFR inhibitors (gefitinib, erlotinib, afatinib, and dacomitinib). This evidence concerns the gene EGFR and non-small cell lung carcinoma.